Global Prevalence of Preexisting Antibodies Against Human Adenoviruses, Surveyed from 1962 to 2021

Overview

Journal Intervirology

Specialty Microbiology

Date 2024 Mar 7

PMID 38452738

Authors

Hui Luo

Qian Zhou

Jinqi Feng

Yi Wu

Huangliang Chen

Meihan Mao

Rui Qi

Affiliations

Soon will be listed here.

Abstract

Background: Human adenoviruses (HAdVs) are extensively used as vectors for vaccines development and cancer therapy. People who already have antibodies against HAdVs, on the other hand, would have an impact on the preventative or therapeutic effect. This review focuses primarily on the prevalence of pre-existing antibodies against HAdVs in distinct geographical populations.

Summary: After screening, 64 studies from 31 countries between 1962 and 2021 were selected, totaling 39,427 samples. The total prevalence of preexisting antibodies to HAdVs varied by country or location, ranging from 2.00 to 95.70%. Southeast Asia had the highest prevalence (54.57%) while Europe had the lowest (18.17%). The prevalence in practically all developing nations was higher than in developed nations. Adults have a greater frequency than children and newborns in most nations. The primary HAdV antibody types varied by country. Adults in China, the USA, the United Kingdom, and Belgium had the lowest prevalence of preexisting antibodies against HAdV55, HAdV37, HAdV8, and HAdV36, respectively. Children in the USA, China, the United Kingdom, and Japan had the lowest rates of HAdV48, HAdV11, HAdV8, and HAdV40. The frequency of antibodies differed significantly between military and civilian groups.

Key Messages: Preexisting antibodies against various types of HAdVs differed greatly throughout worldwide populations. Future development of HAdV-vector vaccines and medicines should focus on preexisting antibodies in target groups rather than a "one-size-fits-all" strategy. It might be advantageous in selecting HAdV vectors for studying the prevalence of preexisting antibodies against HAdVs in different locations and people throughout the world.

References

Saderi H, Roustai M, Sabahi F . Antibodies to enteric adenoviruses (Ad40 and Ad41) in sera from Iranian children. J Clin Virol. 2000; 16(2):145-7. DOI: 10.1016/s1386-6532(99)00071-2. View

Rowe W, HUEBNER R, GILMORE L, PARROTT R, WARD T . Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953; 84(3):570-3. DOI: 10.3181/00379727-84-20714. View

Lessan N, Saradalekshmi K, Alkaf B, Majeed M, Barakat M, Lee Z . Obesity and Diabetes in an Arab population: Role of Adenovirus 36 Infection. Sci Rep. 2020; 10(1):8107. PMC: 7229214. DOI: 10.1038/s41598-020-65008-x. View

Vander Wal J, Huelsing J, Dubuisson O, Dhurandhar N . An observational study of the association between adenovirus 36 antibody status and weight loss among youth. Obes Facts. 2013; 6(3):269-78. PMC: 5644750. DOI: 10.1159/000353109. View

Rubicz R, Leach C, Kraig E, Dhurandhar N, Grubbs B, Blangero J . Seroprevalence of 13 common pathogens in a rapidly growing U.S. minority population: Mexican Americans from San Antonio, TX. BMC Res Notes. 2011; 4:433. PMC: 3214184. DOI: 10.1186/1756-0500-4-433. View

Huang D, Hennequi M, Elvachev A, Menguy T, Silvestre N, Yu D . The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China. Arch Virol. 2015; 160(4):1125-30. PMC: 4369289. DOI: 10.1007/s00705-015-2333-2. View

Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X . Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol. 2012; 84(9):1408-14. DOI: 10.1002/jmv.23325. View

Goossens V, deJager S, Grauls G, Gielen M, Vlietinck R, Derom C . Lack of evidence for the role of human adenovirus-36 in obesity in a European cohort. Obesity (Silver Spring). 2009; 19(1):220-1. DOI: 10.1038/oby.2009.452. View

Zhao J, Nishimoto S . An RNA-competitive polymerase chain reaction method for human matrix gamma-carboxyglutamic acid protein mRNA measurement. Anal Biochem. 1995; 228(1):162-4. DOI: 10.1006/abio.1995.1328. View

10.

Geisbert T, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D . Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85(9):4222-33. PMC: 3126236. DOI: 10.1128/JVI.02407-10. View

11.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

12.

Schnurr D . Seroepidemiology of new AIDS-associated adenoviruses among the San Francisco Men's Health Study. J Med Virol. 1996; 50(3):230-6. DOI: 10.1002/(SICI)1096-9071(199611)50:3<230::AID-JMV4>3.0.CO;2-A. View

13.

Siminovich M, Murtagh P . Acute lower respiratory tract infections by adenovirus in children: histopathologic findings in 18 fatal cases. Pediatr Dev Pathol. 2011; 14(3):214-7. DOI: 10.2350/10-05-0838-OA.1. View

14.

Chen W, Xu W, Xie Y, Zhang Y, Wu D, Wang F . Surveillance for respiratory infectious diseases caused by 6 common viruses in a recruit training site in the Northern region of China. Mil Med Res. 2017; 4:10. PMC: 5376280. DOI: 10.1186/s40779-017-0120-y. View

15.

Paris R, Kim J, Robb M, Michael N . Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines. 2010; 9(9):1055-69. DOI: 10.1586/erv.10.106. View

16.

Ye X, Xiao L, Zheng X, Wang J, Shu T, Feng Y . Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations From Southern China. Front Microbiol. 2019; 9:3040. PMC: 6295555. DOI: 10.3389/fmicb.2018.03040. View

17.

Su X, Ma X, Hong Z, Wu H, Wang Y, Chen L . [Epidemiological study of human type 5 adenovirus in Guangzhou using chemiluminescence for neutralizing antibody assay]. Nan Fang Yi Ke Da Xue Xue Bao. 2007; 27(9):1323-6. View

18.

Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B . Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol. 2013; 85(6):1077-84. DOI: 10.1002/jmv.23546. View

19.

Wang X, Xing M, Zhang C, Yang Y, Chi Y, Tang X . Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect. 2015; 3(5):e30. PMC: 4051363. DOI: 10.1038/emi.2014.30. View

20.

Yang W, Zou X, Jiang S, Lu N, Han M, Zhao J . Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions. Vaccine. 2016; 34(46):5579-5586. PMC: 7115419. DOI: 10.1016/j.vaccine.2016.09.043. View